Last reviewed · How we verify
Insulin Degludec / Liraglutide Injectable Product
This combination product uses insulin degludec to provide long-acting basal insulin coverage and liraglutide to stimulate GLP-1 receptors, enhancing insulin secretion and reducing appetite for improved glycemic control.
This combination product uses insulin degludec to provide long-acting basal insulin coverage and liraglutide to stimulate GLP-1 receptors, enhancing insulin secretion and reducing appetite for improved glycemic control. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Degludec / Liraglutide Injectable Product |
|---|---|
| Also known as | Insulin Degludec/Liraglutide |
| Sponsor | University of Palermo |
| Drug class | Insulin/GLP-1 receptor agonist combination |
| Target | Insulin receptor; GLP-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin degludec is an ultra-long-acting basal insulin analog that provides steady glucose control over 24+ hours. Liraglutide is a GLP-1 receptor agonist that stimulates insulin secretion in response to meals, slows gastric emptying, and promotes satiety. Together, they address both fasting and postprandial glucose levels while supporting weight loss.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
- Injection site reactions
- Headache
Key clinical trials
- A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects (PHASE1)
- Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients (PHASE4)
- Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: